Navigation Links
Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
Date:12/12/2011

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Receptos Inc. announced today the establishment of a collaboration with Ono Pharmaceutical Co., Ltd. (Osaka, Japan) for the research and development of small molecule modulators of an undisclosed G-protein coupled receptor (GPCR) target. Under the terms of the agreement, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and drive Ono's structure-based drug design efforts. Receptos will receive from Ono an up-front payment, research funding and success payments, including product development milestones based on the progress of the collaboration.

"The selection of a collaborative target in the bioactive lipid class of GPCR receptors, where Ono has built a robust portfolio of products, is well matched with our company's expertise in the related sphingosine-1-phosphate receptor (S1P) target class," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "Furthermore, this collaboration represents another opportunity for us to realize the significant value of our technology platform by adding non-dilutive funding to Receptos as we build and advance our own pipeline of clinical-stage drug candidates."

Added Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono, "Receptos' GPCR protein crystal structure determination platform technology is highly regarded by Ono. This collaboration will strengthen Ono's drug discovery capability in our area of expertise and lead to enriching our pipeline of innovative drugs that can fulfill unmet medical needs."

About the GPCR Class of Targets

GPCRs are a class of cell surface receptors conjugated with a G-protein, the signaling pathway of which is initiated by binding between the receptor and a hormone or bioactive molecule. GPCR targeted therapeutics comprise major drug classes
'/>"/>

SOURCE Receptos Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
2. Medical Policy Guideline for Trofile(TM) Established By Wellpoint, Inc.
3. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
4. Facet Solutions Establishes Corporate Headquarters and Expands Executive Team
5. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
6. Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
7. Environmental Power Corporation and Organix, Inc. Establish Alliance to Produce High Value Soil Amendment Products
8. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
9. Imugene and Merial Establish Strategic Alliance
10. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
11. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... May 12 /PRNewswire/ - Cytochroma today announced that ... Chief Financial Officer (CFO).,Mr. Wieland, 63, brings to ... financial management, at both public and private companies, ... "Rich has strong leadership skills, extensive experience managing,finance ...
... Lasers that emit ultrashort pulses of light are ... eye surgery, spectroscopy and controlling chemical reactions. But ... distortions caused by lenses and other optical components ... , To better understand the distortions, researchers at ...
... On Diagnostic Products and Target Validation, ... announced today,that SomaLogic and Otsuka Pharmaceutical Co., ... SomaLogic,s proprietary aptamer technology,to discover and develop ... that will enhance Otsuka,s pharmaceutical discovery and ...
Cached Biology Technology:Cytochroma Appoints R. Richard Wieland II As CFO 2New technique measures ultrashort laser pulses at focus 2New technique measures ultrashort laser pulses at focus 3SomaLogic and Otsuka Enter Into Research Collaboration 2SomaLogic and Otsuka Enter Into Research Collaboration 3
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... led by a Michigan State University professor has discovered a link ... one of the disease,s most common and potentially blindness-causing complications. ... vessels in the retina that affects up to 80 percent of ... to the nerves found in bone marrow that leads to the ...
... beetle, a pest that feasts on corn roots and corn ... the U.S., also can survive on the perennial grass ... likely be grown alongside corn, researchers report. Rootworm beetle ... and adult beetles will lay their eggs at the base ...
... COLD SPRING HARBOR, N.Y. (Jan. 5, 2010) ... proteomics have dramatically increased the need for quantitative reasoning ... the most routine informatics tools rely on statistical assumptions ... scientific results are to be correct, understood, and exploited ...
Cached Biology News:MSU researcher links diabetic complication, nerve damage in bone marrow 2Miscanthus, a biofuels crop, can host western corn rootworm 2Miscanthus, a biofuels crop, can host western corn rootworm 3New handbook for biologists who need more competence or confidence in statistics 2
... DALTsix Gradient Maker, 1. Modular system ... 2-D electrophoresis.Run up to six lab-cast ... cm) simultaneously.Use with 18- or 24-cm ... pre-assembled hinged gel cassettes.Innovative design simplifies ...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
albumin from bovine serum (BSA), 2,4-dinitrophenylated (DNP-BSA)...
Request Info...
Biology Products: